Compare NWTG & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | CNSP |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 5.9M |
| IPO Year | N/A | 2019 |
| Metric | NWTG | CNSP |
|---|---|---|
| Price | $0.96 | $5.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 40.1K | ★ 2.1M |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.21 | N/A |
| Revenue Next Year | $40.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.73 |
| 52 Week High | $2.23 | $10.59 |
| Indicator | NWTG | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 56.07 |
| Support Level | $0.82 | $2.01 |
| Resistance Level | $2.01 | $8.56 |
| Average True Range (ATR) | 0.10 | 1.04 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 18.15 | 34.95 |
Newton Golf Co Inc is a technology-forward golf company dedicated to revolutionizing the sport with cutting-edge, high-performance products. The company's expanding portfolio includes golf shafts, putters, grips, and other golf-related accessories designed for golfers of all skill levels. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf, as well as through mass merchants and corporate customers in the Americas, Asia, and Europe.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.